Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients

Circulation: Cardiovascular Quality and Outcomes

Volumn 1, Issue 1, 2008, Pages 12-20

  Weintraub, William S ^a   Boden, William E ^b   Zhang, Zugui ^a   Kolm, Paul ^a   Zhang, Zefeng ^c   Spertus, John A ^d   Hartigan, Pamela ^e   Veledar, Emir ^c   Jurkovitz, Claudine ^a   Bowen, Jim ^a   Maron, David J ^f   O'Rourke, Robert ^g   Dada, Marcin ^h   Teo, Koon K ⁱ   Goeree, Ron ⁱ   Barnett, Paul G ^g  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

^b GATES VASCULAR INSTITUTE AT KALEIDA HEALTH   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h HARTFORD HOSPITAL   (United States)

ⁱ MCMASTER UNIVERSITY   (Canada)

Author keywords

Angina; Coronary disease; Cost benefit analysis; Epidemiology; Stents

Indexed keywords

AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 74349084304     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.108.798462     Document Type: Article

References (31)

1. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, Grinfeld L, Gibbons RJ, Ribeiro EE, DeWood MA, Ribichini F. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997;278:2093-2098. (Pubitemid 28016233)
2. Parisi AF, Folland ED, Hartigan P. Veterans Affairs ACME Investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med. 1992;326:10 -16.
3. RITA-2 trial participants. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet. 1997;350:461-468.
4. Pitt B, Waters D, Brown WV, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS. Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999; 341:70 -76. (Pubitemid 29314237)
5. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005;293:2908-2917. (Pubitemid 41029145)
6. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation. 2005;111:2906 -2912. (Pubitemid 40823048)
7. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516. (Pubitemid 46588415)
8. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, Zhang Z, Jurkovitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Boden J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree R, Barnett PG, Teo KK, Boden WE. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677-687.
9. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GB, Berman DS, Weintraub WS. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program No. 424. Am Heart J. 2006;151:1173-1179. (Pubitemid 44172871)
10. Weintraub WS, Barnett P, Chen S, Hartigan P, Casperson P, O'Rourke R, Boden WE, Lewis C, Veledar E, Becker E, Culler S, Kolm P, Mahoney EM, Dunbar SB, Deaton C, O'Brien B, Goeree R, Blackhouse G, Nease R, Spertus J, Kaufman S, Teo K. Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial. Am Heart J. 2006;151:1180 -1185. (Pubitemid 43866611)
11. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., Jacobs AK, Kern MJ, King SB III, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006; 113:156 -175. (Pubitemid 43958502)
12. Wyrwich KW, Spertus JA, Kroenke K, Tierney WM, Babu AN, Wolinsky FD. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. Am Heart J. 2004; 147:615-622. (Pubitemid 38900445)
13. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press 1996.
14. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, United Kingdom: Oxford Medical Publications; 1987.
15. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyorala K, Miettinen T, Haghfelt T, Faergeman O, Thorgerisson G, Jonsson B, Schwartz JS. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93:1796 -1802.
16. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336:332-336. (Pubitemid 27057183)
17. Centers for Medicare and Medicaid Services. Available at: http:// www.cms.hhs.gov/MedicareFeeforSvcPartsAB/03-MEDPAR.asp. Accessed August 22, 2008.
18. Yang X, Li J, Shoptow S. Multiple partial imputation for longitudinal data with missing values in clinical trials. Department of Statistics, UCLA; Department of Statistics Papers. Paper No. 2005010102. January 1, 2005. Available at: http://repositories.cdlib.org/uclastat/papers/2005010102/. Accessed May 1, 2007.
19. CEA Registry. Center for the Evaluation of Value & Risk in Health. Tufts Medical Center Web page. Available at: https://research.tuftsnemc. org/cear. Accessed July 4, 2008.
20. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history: a life course analysis of the original Framingham Heart Study cohort. Eur Heart J. 2002;23:458-466. (Pubitemid 35204185)
21. Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos LA, DiBattiste PM, Cannon CP, Weintraub WS. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002;288:1851-1858. (Pubitemid 35168140)
22. Caro J, Migliaccio-Walle K, Ishak KJ, Weintraub WS Estimating life-years lost due to atherothrombotic events: flexible survival functions to use in disease modeling. J Am Coll Cardiol. 2004;43:425A. Abstract
23. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993.
24. Oakley JE, O'Hagan A. Probabilistic sensitivity analysis of complex models: a Bayesian approach. J R Stat Soc. 2004;66:751-769. (Pubitemid 39015911)
25. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statistics- 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117: e25-e146.
26. Mittelmark MB, Psaty BM, Rautaharju PM, Fried LP, Borhani NO, Tracy RP, Gardin JM, O'Leary DH. Prevalence of cardiovascular diseases among older adults: the Cardiovascular Health Study. Am J Epidemiol. 1993;137:311-317. (Pubitemid 23090465)
27. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008; 117:1283-1291. (Pubitemid 351365675)
28. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation. 1982;66(pt 2):III-56 -III-66.
29. Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascularization for chronic stable angina: analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med. 1990;113:852-871.
30. Claude J, Schindler C, Kuster GM, Schwenkglenks M, Szucs T, Buser P, Osswald S, Kaiser C, Gradel C, Estlinbaum W, Richenbacher P, Pfisterer M. Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease: findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). Eur Heart J. 2004;25:2195-2203. (Pubitemid 39592420)
31. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: part II. Circulation. 2002;106:626-630. (Pubitemid 34827715)